MC Donohue

Michael C Donohue, PhD

Professor, Department of Neurology

Associate Director of Biostatistics
USC Epstein Family Alzheimer’s Therapeutic Research Institute
Co-Lead, Biostatistics Unit
Alzheimer’s Clinical Trial Consortium
Keck School of Medicine of USC
University of Southern California
9860 Mesa Rim Rd
San Diego, CA 92121
mdonohue@usc.edu

About

Michael Donohue is Professor of Neurology at the Keck School of Medicine and Associate Director of Biostatistics at the Epstein Family Alzheimer’s Therapeutic Research Institute (ATRI). He received his PhD in Mathematics from the University of California, San Diego. Dr. Donohue applies novel statistical methods to data from natural history studies and clinical trials to better understand the multivariate course of markers of Alzheimer’s progression, and design innovative clinical trials to prevent or slow the progression of disease. He has studied the risk of cognitive decline associated with elevated brain amyloid in cognitively normal individuals; and helped design the first intervention in asymptomatic Alzheimer’s, the Anti-Amyloid Treatment for Asymptomatic Alzheimer’s (the A4 Study; in collaboration with Eli Lilly), and its primary outcome measure, the Preclinical Alzheimer Cognitive Composite. He has been awarded grants to develop innovative statistical approaches for Alzheimer’s from the National Institute on Aging; the Alzheimer’s Association, Michael J. Fox Foundation, and W. Garfield Weston Foundation; and the Clinical and Translation Research Institute of the University of California, San Diego